Boehringer Ingelheim Pharmaceuticals Inc., based in Ridgefield, said recently its Stiolto Respimat product, a once-a-day inhaled medicine ”“ approved last year for chronic obstructive pulmonary disorder ”“ outperformed a European formulation of a pair of different drugs used together.
The study results are published online in the Journal of Chronic Obstructive Pulmonary Disease. The study investigated the impact of Stiolto Respimat on lung function among moderate to severe COPD patients. The European model used two drugs that included a “long-acting beta agonist, salmeterol, and an inhaled corticosteroid fluticasone propionate.”
The study involved 15,000 patients.
“The publication of these results further demonstrates the ability of Stiolto Respimat to safely and effectively improve lung function in COPD patients,” said Dr. James Donohue as part of the Boehringer statement announcing the results. He is a professor of medicine and former chief of the division of pulmonary and critical care medicine at the University of North Carolina at Chapel Hill School of Medicine. “These newly published data show a lung function improvement among COPD patients with Stiolto Respimat across a range of commonly used measures of lung function.”
In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion. Research and development expenditure corresponds to 19.9 percent of its net sales.
